According to the CDC, approximately six million Americans are living with Alzheimer's disease, but access to experimental, potentially life-saving drugs is limited. For impacted veterans, the Veterans Health Administration is looking for ways to provide that access.
Last year, Biogen, in partnership with Japanese drug company Eisai, announced that the drug called Leqembi showed promise in slowing cognitive decline in Alzaheimer's patients by 27 percent. The VHA announced it will shell out more than $26,000 annually for each veteran on Leqembi. If the FDA grants a full approval by July 6, Medicare and Medicaid services said it would immediately provide broad coverage of the drug to customers.
The experimental treatment received Accelerated Approval by the Food and Drug administration earlier this year. The specific pathway to approval had been introduced by the agency to provide speedier clearance on drugs that treat serious conditions.
Last month the Centers for Medicare and Medicaid Services declined to provide unrestricted coverage of the drug because "there is not yet evidence meeting the criteria for reconsideration."
"This standard differs from the criteria used by the FDA to assess whether medications are safe and effective. We are aware that additional publications may be forthcoming that include information relevant to the questions included in the current NCD," the agency added in its statement.
The U.S. Food and Drug Administration has approved selling overdose antidote naloxone over-the-counter, marking the first time a opioid treatment drug will be available without a prescription.
Millions of Americans could lose access to Medicaid on April 1, and Joe Dunn, senior vice president of public policy at the National Association of Community Health Centers, joined Cheddar News' anchor Shannon LaNier to discuss what this means for public health.
One third of Americans don't have access to primary care providers in their communities, according to a study from the National Association of Community Health Centers published last month.
Neuralink, Elon Musk's brain implant venture, is reaching out to major U.S. neurosurgery centers to potentially begin testing its devices on humans, according to a Reuters report.
A Minnesota utility began shutting down a nuclear power plant near Minneapolis on Friday after discovering water containing a low level of radioactive material was leaking from a pipe for the second time. While the utility and health officials say it is not dangerous, the issue has prompted concerns among nearby residents and raised questions about aging pipelines.
